Haemodynamic effects of dopexamine and nitric oxide synthase inhibition in healthy and endotoxaemic sheep

European Journal of Pharmacology

Volumn 333, Issue 2-3, 1997, Pages 181-186

  Waurick, René ^a   Bone, Hans Georg ^a   Meyer, Jörg ^a   Booke, Michael ^a   Andreas Meissner ^a   Prien, Thomas ^a   Van Aken, Hugo ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Abstract; Dopexamine; Hyperdynamic circulation; Nitric oxide (NO) synthase inhibition

Indexed keywords

DOPEXAMINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOTOXEMIA; FEMALE; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; SHEEP;

ADRENERGIC BETA-AGONISTS; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; ENDOTOXEMIA; ENDOTOXINS; ENZYME INHIBITORS; FEMALE; HEMODYNAMIC PROCESSES; INFUSIONS, INTRAVENOUS; LUNG; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; OXYGEN CONSUMPTION; SALMONELLA TYPHI; SHEEP; VASODILATOR AGENTS;

EID: 0030931515     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01132-1     Document Type: Article

References (23)

1. Booke M., Meyer J., Lingnau W., Hinder F., Traber L., Traber D. Use of nitric oxide synthase inhibitors in animal models of sepsis. New Horiz. 3:1995;123-138.
2. Colardyn F.C., Vandenbogaerde J.F., Vogelaers D.P., Verbeke J.H. Use of dopexamine hydrochloride in patients with septic shock. Crit. Care Med. 17:1989;999-1003.
3. De Wit C., Von Bismarck P., Pohl U. Synergistic action of vasodilators that increase cGMP and cAMP in the hamster cremaster microcirculation. Cardiovasc. Res. 28:1996;1513-1518.
4. Foulds R.A. Clinical development of dopexamine hydrochloride (Dopacard) and an overview of its haemodynamic effects. Am. J. Cardiol. 62:1988;41C-45C.
5. Gibson R.L., Berger J., Redding G.J., Standaert T.A., Mayock D.E., Truog W.W. Effect of nitric oxide synthase inhibition during group B streptococcal sepsis in neonatal piglets. Pediatr. Res. 36:1994;776-783.
6. Goldberg L.I., Bass A.S. Relative significance of dopamine receptors, beta adrenoceptors and norepinephrine uptake inhibition in the cardiovascular actions of dopexamine hydrochloride. Am. J. Cardiol. 62:1988;37C-40C.
7. Gomez-Jimenez J., Salgado A., Mourelle M., Martin M.C., Segura R.M., Peracaula R., Moncada S. L-arginine: nitric oxide pathway in endotoxaemia and human septic shock. Crit. Care Med. 23:1995;253-258.
8. Graves J., Poston L. Beta-adrenoceptors agonist mediated relaxation of rat isolated resistance arteries: A role for the endothelium and nitric oxide. Br. J. Pharmacol. 108:1993;631-637.
9. Hollenberg S.M., Cunnion R.E., Zimmerberg J. Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to catecholamines in septic rats. Am. J. Physiol. 264:1993;H660-H663.
10. Kilbourn R.G., Cromeens D.M., Chelly F.D., Griffith O.W. N-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxaemic dogs. Crit. Care Med. 22:1994;1835-1840.
11. Landin L., Lorente J.A., Renes E., Canas P., Jorge P., Liste D. Inhibition of nitric oxide synthesis improves the vasoconstrictive effect of noradrenaline in sepsis. Chest. 106:1994;250-256.
12. MacGregor D.A., Prielipp R.C., Butterworth J.F., James R.L., Royster R.L. Relative efficacy and potency of beta-adrenoceptors agonists for generating cAMP in human leukocytes. Chest. 109:1996;194-200.
13. Meyer J., Hinder F., Stothert J., Traber L., Herdorn N., Flynn J.T., Traber D. Increased organ blood flow in chronic endotoxaemia is reversed by nitric oxide synthase inhibition. J. Appl. Physiol. 76:1994;2785-2793.
14. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43:1991;109-142.
15. Petros A., Lamb G., Moncada S., Bennett D., Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc. Res. 28:1994;34-39.
16. Schmidt H., Secchi A., Wellmann R., Bach A., Böhrer H., Martin E. Dopexamine maintains intestinal villus blood flow during endotoxaemia in rats. Crit. Care Med. 24:1996;1233-1237.
17. Smith G.W., O'Connor S.E. An introduction to the pharmacologic properties of Dopacard (dopexamine hydrochloride). Am. J. Cardiol. 62:1988;9C-17C.
18. Smith G.W., Hall J.C., Farmer J.B., Simpson W.T. The cardiovascular actions of dopexamine hydrochloride, an agonist at dopamine receptors and beta2-adrenoceptors in the dog. J. Pharm. Pharmacol. 39:1987;636-641.
19. Stephan H., Sonntag H., Henning H., Yoshimine K. Cardiovascular and renal haemodynamic effects of dopexamine: comparison with dopamine. Br. J. Anaesth. 65:1990;380-387.
20. Szabo C. Alterations in nitric oxide productions in various forms of septic shock. New Horiz. 3:1995;2-32.
21. VanDerStarre P.J., Rosseel P.M. Dopexamine hydrochloride after coronary bypass grafting. Am. J. Cardiol. 62:1988;78C-82C.
22. Wang Y.-X., Poon K.S., Randell D.J., Pang C.Y. Endothelium-derived nitric oxide partially mediates salbutamol-induced vasodilatations. Eur. J. Pharmacol. 250:1993;335-340.
23. Wang Y.-X., Lim S.L., Pang C.Y. Increase by N-nitro-L-arginin methyl ester (L-NAME) of resistance to venous return in rats. Br. J. Pharmacol. 114:1995;1454-1458.